-

AbCellera to Present Virtually at the BofA Securities – Tech Solutions for Drug Discovery Conference

VANCOUVER--(BUSINESS WIRE)--AbCellera (Nasdaq: ABCL) today announced that executives from the Company will present virtually at the BofA Securities  – Tech Solutions for Drug Discovery Conference on Monday, September 20, 2021, at 9:00 a.m. Pacific Time.

A live audio webcast of the presentation may be accessed through a link that will be posted on AbCellera’s Investor Relations website. A replay will be available through the same link following the presentation.

About AbCellera Biologics Inc.

AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, empowering them to move quickly, reduce costs, and tackle the toughest problems in drug development. For more information, please visit www.abcellera.com.

Source: AbCellera Biologics Inc.

Contacts

Inquiries
Media: Jessica Yingling, Ph.D.; media@abcellera.com, +1(236)521-6774
Business Development: Neil Berkley, Ph.D.; bd@abcellera.com, +1(604)559-9005
Investor Relations: Melanie Solomon; ir@abcellera.com, +1(778)729-9116

AbCellera

NASDAQ:ABCL

Release Summary
AbCellera to Present Virtually at the BofA Securities – Tech Solutions for Drug Discovery Conference
Release Versions
$Cashtags

Contacts

Inquiries
Media: Jessica Yingling, Ph.D.; media@abcellera.com, +1(236)521-6774
Business Development: Neil Berkley, Ph.D.; bd@abcellera.com, +1(604)559-9005
Investor Relations: Melanie Solomon; ir@abcellera.com, +1(778)729-9116

Social Media Profiles
More News From AbCellera

AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

VANCOUVER, British Columbia--(BUSINESS WIRE)--AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants...

AbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to-Severe VMS Due to Menopause on Monday, August 10, 2026

VANCOUVER, British Columbia--(BUSINESS WIRE)--AbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to-Severe VMS Due to Menopause on Aug. 10, 2026...
Back to Newsroom